Research programme: Chronic urticaria therapeutics - Enanta Pharmaceuticals
Latest Information Update: 12 Aug 2024
At a glance
- Originator Enanta Pharmaceuticals
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Proto-oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic urticaria
Most Recent Events
- 05 Aug 2024 Enanta Pharmaceuticals plans to select a leading clinical candidate for Chronic-urticaria from this research programme by Q4 2024
- 06 May 2024 Preclinical trials in Chronic-urticaria in USA (PO) before May 2024
- 06 May 2024 Pharmacodynamics and pharmacokinetics data from the preclinical studies in Chronic-urticaria released by Enanta Pharmaceuticals